K562 Cells — The Cornerstone Cell Line for Chronic Myeloid Leukemia Research

Introduction

K562 Cells, also designated K-562, represent one of the most widely studied human leukemic cell lines in biomedical research. Established from a pleural effusion, the line has become the prototypical in vitro model of BCR-ABL1-positive chronic myelogenous leukemia (CML) in blast crisis. Since its original characterisation in the mid 1970s, K562 has been employed across an extraordinary breadth of research disciplines, including targeted cancer therapy, natural killer (NK) cell immunology, hematopoiesis, erythropoiesis, and drug screening. Its consistent suspension growth, well-defined BCR-ABL fusion oncoprotein expression, and sensitivity to tyrosine kinase inhibitors have made it an indispensable tool for understanding myeloid leukemia biology. Today, K562 remains a reference standard in cytotoxicity assays, genomic studies, and the preclinical evaluation of novel anticancer compounds.

Key Takeaways

• K562 is a BCR-ABL1-positive human erythroleukemic cell line derived from a CML blast crisis pleural effusion.
• The line expresses the BCR-ABL fusion oncoprotein, making it the standard model for studying tyrosine kinase inhibitor responses.
• K562 cells grow in suspension and lack MHC class I (HLA) surface expression, making them the gold-standard target in NK cell cytotoxicity assays.
• The line carries a homozygous TP53 frameshift mutation and a BCR-ABL gene fusion involving BCR exon 14 and ABL1 exon 2.
• K562 is extensively used for anticancer drug screening, miRNA research, hematopoietic differentiation studies, and ENCODE genomic analyses.
• The pseudo-triploid karyotype and well-characterised genome make K562 a robust, reproducible model for multi-omic investigations.

What is K562?

K562 was derived from the pleural effusion of a 53-year-old female patient diagnosed with BCR-ABL1-positive chronic myelogenous leukemia in blast crisis. The cell line was originally characterised in 1975 and rapidly became a foundational model for understanding myeloid leukemia biology. It is classified as an erythroleukemic line, bearing hallmarks of both undifferentiated granulocyte and erythrocyte precursors. At the genetic level, K562 carries a BCR-ABL1 gene fusion in which BCR exon 14 is joined to ABL1 exon 2, producing the constitutively active tyrosine kinase that drives leukemogenesis. Additionally, the line harbours a homozygous TP53 frameshift mutation (p.Gln136fs*13; c.406_407insC), which further shapes its cellular behaviour and drug response profile. The Cellosaurus accession for K562 is CVCL_0004.

K562 Cell Culture Information

K562 – low confluency

K562 – high confluency

Advantages of K562 Cells

K562 cells offer several exceptional advantages that explain their enduring popularity in leukemia research. Their suspension growth eliminates the need for enzymatic detachment procedures, simplifying routine culture and experimental workflows. The cells proliferate rapidly and reliably, reaching high densities with viability exceeding 90% after the first passage following thaw. This robust growth consistency reduces experimental variability and makes scale-up straightforward. Furthermore, K562 lacks detectable surface MHC class I (HLA) expression, a property that renders it exquisitely sensitive to NK cell-mediated killing. This makes K562 the gold-standard target cell line used in virtually all NK cell cytotoxicity assays worldwide.

At the molecular level, the constitutive BCR-ABL fusion kinase provides a well-defined oncogenic driver that faithfully recapitulates the key signalling abnormalities of CML in blast crisis. Researchers can therefore study tyrosine kinase inhibitor responses in a controlled, reproducible system. The line's pseudo-triploid karyotype and extensively characterised genome — including its prominent role as a primary ENCODE reference cell line — mean that large volumes of publicly available transcriptomic, epigenomic, and chromatin-accessibility data exist. These resources greatly accelerate hypothesis generation and data interpretation in genomics-focused studies.

Limitations of K562 Cells

Despite its widespread use, K562 carries important limitations that researchers should consider. The homozygous TP53 frameshift mutation means the line lacks functional p53-dependent apoptotic responses, which can confound studies investigating DNA damage pathways or p53-dependent drug mechanisms. Because K562 originates from a blast crisis stage of CML, it may not fully represent earlier, more indolent phases of the disease. This temporal specificity should be considered when attempting to model early CML pathogenesis or drug responses in chronic-phase cells.

Extended in vitro passaging can introduce additional chromosomal aberrations, potentially causing phenotypic drift between laboratory stocks. Different institutions may therefore maintain K562 sublines with subtly divergent karyotypes or gene expression profiles, complicating cross-laboratory comparisons. The absence of MHC class I expression, while advantageous for NK assays, also means K562 cannot be used to study HLA-restricted T-cell responses. Finally, as a suspension cell line, K562 is unsuited for experimental platforms requiring surface attachment, limiting its use in certain microfluidic or wound-healing assay formats.

Applications of K562 Cells

CML, BCR-ABL Signaling, and Targeted Therapy

K562 cells have served as the primary in vitro model for studying BCR-ABL-driven oncogenic signalling and the mechanisms of tyrosine kinase inhibitor action. The seminal characterisation of the K562 cell line as a human erythroleukemic line by Andersson et al. (1979) established that these cells harboured unique hematopoietic precursor properties and an antigen profile consistent with early myeloid and erythroid differentiation. [1] That foundational study provided the biological framework upon which decades of CML drug development have been built, confirming K562 as the definitive cellular benchmark for BCR-ABL research.

More recent molecular investigations have continued to refine our understanding of BCR-ABL signalling networks using K562 cells. Akbari-Ardabili et al. explored time-resolved Hippo-YAP pathway responses in K562 cells treated with imatinib, demonstrating coordinated upregulation of Hippo pathway transcripts at 12 hours and a subsequent delayed microRNA response by 48 hours. [2] These findings illuminate early molecular events linking BCR-ABL1 inhibition to leukemic cell fate decisions. In a parallel line of investigation, Antonenko et al. examined the spatial relationship between FNBP1 and the BCR-ABL oncoprotein using immunofluorescence and confocal microscopy in K562 cells. [3] Their bioinformatic analysis suggested that FNBP1 participates in BCR-ABL-associated signalling networks involved in cytoskeletal remodelling, highlighting a potential new target in CML therapy.

The JAK/STAT signalling axis, closely linked to BCR-ABL activity, has also been examined in K562 cells. Li et al. demonstrated that vitamin K4 inhibited leukemic cell proliferation by inducing cell cycle arrest and mitochondrial-mediated apoptosis, effects associated with modulation of the JAK/STAT pathway, and confirmed these findings using K562-based xenograft models. [4] A broader multi-omic study by Lukic et al. interrogated STAT family activation across tumour types, drawing on K562 chromatin-binding and transcriptomic data to contextualise oncogenic STAT3 and STAT5 activity in myeloid malignancies. [5] Bone marrow-derived mesenchymal stem cells (BMSCs) have also been shown to promote apoptosis and alter cell cycle distribution in K562 cells through secreted cytokines, establishing a paracrine mechanism with translational relevance for CML microenvironment research.

NK Cell Immunology and Cytotoxicity Assays

The absence of HLA class I surface expression on K562 cells underpins their central role as target cells in NK cell functional assays. Kantakamalakul et al. developed an EGFP-K562 stable cell line in which enhanced green fluorescent protein was stably expressed, enabling NK cell cytotoxicity measurement by flow cytometry without the need for radioactive chromium-51 release assays. [6] This approach correlated strongly with the standard ⁵¹Cr release assay (r = 0.87–0.89, p < 0.001) and demonstrated that a two-hour incubation yielded results comparable to four-hour protocols, substantially streamlining cytotoxicity measurements.

K562 cells continue to serve as the benchmark comparator in NK cell expansion and engineering studies. Lim et al. directly compared the unmodified ARH-77 feeder cell line with K562 for ex vivo NK cell expansion from peripheral blood mononuclear cells, using K562 as the established positive-control feeder to evaluate new engineering strategies. [7] Both lines were further modified to co-express B7-H6, CD137L, IL-15, and IL-15Rα, demonstrating that K562 remains a key engineering scaffold for generating clinically relevant NK cell products for adoptive immunotherapy.

Mechanistic studies of NK cell activation have also capitalised on the K562 system. Badami et al. used genome-wide CRISPR screens in K562 cells to identify BAP1 as a key genetic determinant of susceptibility to NK cell-mediated killing. [8] BAP1 knockout cells exhibited reduced HLA class I induction upon IFN-γ stimulation and enhanced NK cell degranulation, establishing an important link between epigenetic regulation and innate immune evasion in myeloid leukemia. Separately, γδ T cell studies by Cazote et al. used K562 cells as stimulatory targets to assess functional responses in COVID-19 patients of varying disease severity. [9]

Anticancer Drug Screening and Natural Product Research

K562 cells are routinely incorporated into anticancer compound screening panels due to their well-characterised pharmacology and predictable growth kinetics. Egorova et al. synthesised a series of novel acetylenic phosphonates and identified three dialkyl derivatives with pronounced antiproliferative activity against K562, achieving an IC50 of 6 μg/ml. [10] These compounds additionally caused significant actin cytoskeleton disorganisation and reduced K562 cell motility, suggesting a dual mechanism relevant to CML invasion biology. In a natural products context, Jia et al. isolated cassane-type diterpenoids from Caesalpinia pulcherrima seeds and screened them against a panel including K562, with compounds 5 and 7 displaying IC50 values in the range of 9.61 to 27 μM across multiple cancer lines. [11]

Plant-derived terpenoids and phenolic scaffolds have consistently shown activity against K562 cells in compound library evaluations. Nazemosadat-Arsanjani et al. isolated diterpenoids including ortho-quinones zhumerianone C and aethiopinone from Salvia majdae, demonstrating potent cytotoxicity with IC50 values of 0.9–6.8 μM in cancer cell panels that included K562. [12] Zhao et al. reported eight novel eudesmane-type sesquiterpenoids from Magnolia grandiflora fruits and evaluated their cytotoxic activities against K562, A549, HepG2, MDA-MB-231, and SW480 cell lines alongside anti-inflammatory profiling. [13] Tiuleanu et al. synthesised novel salicylidene hydrazones of indole-2-carboxylic acid and tested antiproliferative potency in a panel including K562, highlighting the line's utility as a standard reference in medicinal chemistry campaigns. [14]

Anticancer drug investigations using K562 extend to well-characterised flavonoids and vitamins as well as novel synthetic scaffolds. Quercetin has been shown to promote cell cycle arrest and apoptosis in K562 cells, with interactions involving heat shock proteins playing a key modulatory role. Acetylshikonin induced S-phase cell cycle arrest in K562 cells at an IC50 of approximately 1.13 μM at 48 hours, with accompanying BCR-ABL depletion confirming on-target activity in the CML context. These studies collectively illustrate how K562's defined BCR-ABL background and consistent drug response profile make it an indispensable tool in preclinical oncology screening.

MicroRNA and Epigenetic Regulation in Leukemia

K562 cells have become a preferred model for dissecting microRNA-mediated regulation of leukemic cell behaviour. Lachinani et al. observed downregulation of miR-143 and miR-199 in both CML and AML cell lines, with K562 displaying the strongest negative correlation between these miRNAs and the RNA-binding protein Musashi2. [15] Overexpression of miR-143 and miR-199 in K562 cells reduced both mRNA and protein levels of Musashi2, leading to decreased cell proliferation and invasiveness. miR-143 exerted a quantitatively greater anti-proliferative effect, highlighting differential functional roles for individual miRNAs targeting the same RNA-binding protein.

The Hippo-YAP signalling pathway represents an emerging regulatory axis in CML, and K562 cells have enabled time-resolved dissection of its microRNA interactions. The study by Akbari-Ardabili et al. profiled core Hippo pathway genes and associated microRNAs in K562 cells over a 48-hour imatinib treatment window, revealing a temporal disconnect between early mRNA upregulation and delayed microRNA responses. [2] These findings suggest that microRNA-mediated feedback may buffer early Hippo pathway activation in CML cells, with implications for understanding residual disease after targeted therapy. Chromatin-binding analysis using K562-derived data also contributed to the STAT family evolutionary study by Lukic et al., providing insights into context-dependent transcription factor regulation. [5]

Hematopoiesis and Erythropoiesis Research

K562 cells retain the capacity for multi-lineage differentiation, making them a valuable tool in hematopoiesis and erythropoiesis research. The line can be induced to differentiate toward erythroid, megakaryocyte, and macrophage lineages, recapitulating aspects of normal progenitor commitment in a tractable cell culture system. Research into steamed Panax notoginseng saponins (SPNS) utilised K562 cells as part of an erythroid progenitor proliferation model, with multiomics analysis identifying cAMP/PI3K/AKT/cGMP pathways as mediators of the blood-enriching properties relevant to cyclophosphamide-induced anemia. [16]

Polysaccharide research has also drawn on K562's erythroid properties. Hu et al. investigated electron beam irradiation as a pretreatment to enhance extraction and modify the biofunctional properties of Angelica sinensis polysaccharides, including immunomodulatory and hematopoiesis-supporting activities assessed in part using K562 as a cellular model. [17] These traditional medicine-oriented studies reflect K562's broad utility as a hematopoietic reference line bridging ethnopharmacology and modern cell biology.

The erythroleukaemic identity of K562 was rigorously established in the foundational 1979 Andersson et al. study, which characterised its erythroid precursor antigen profile and placed it in the broader landscape of human leukemic cell lines. [1] This work underpins subsequent differentiation studies that have used K562 to model haemoglobin switching, globin gene regulation, and the response of immature erythroid progenitors to pharmacological stimuli. A doxorubicin-resistant K562 subline derived in subsequent characterisation work has further enabled drug-resistance modelling in an erythroleukaemic background, extending the line's utility for studying multidrug resistance mechanisms.

Conclusion

K562 cells occupy a uniquely central position in hematological research, serving simultaneously as the definitive model of BCR-ABL1-positive chronic myelogenous leukemia, the gold-standard target cell in NK cell cytotoxicity assays, and a versatile platform for anticancer drug screening and hematopoiesis studies. From the founding characterisation of the erythroleukemic cell line in 1979 [1] through to cutting-edge CRISPR screens, Hippo-YAP pathway analyses, and natural product evaluations, K562 has demonstrated exceptional scientific longevity. Its well-defined BCR-ABL fusion oncoprotein, absence of HLA class I expression, suspension growth habit, and extensively catalogued genome collectively make it irreplaceable in leukemia and immunology laboratories worldwide. Researchers requiring a reliable, extensively validated CML model for targeted therapy studies, immune function assays, or genomics research will find K562 an indispensable resource. Visit cytion.com to explore full product specifications or to order K562 cells for your research programme.

Key Publications

1. Andersson LC, Nilsson K, Gahmberg CG (1979) K562--a human erythroleukemic cell line. Int. J. Cancer. PMID: 367973
2. Akbari-Ardabili S, Aghazadeh S, Imani M (2026) Time-resolved Hippo-YAP transcript and microRNA responses to imatinib in K562 chronic myeloid leukemia cells with exploratory analysis of CD34⁺ progenitor transcriptomes. Molecular biology reports. PMID: 42201499
3. Antonenko S, Gurianov D, Kravchuk I (2026) FNBP1 in Chronic Myeloid Leukemia: Spatial Association with BCR-ABL and Potential Implications for Targeted Therapy. Experimental oncology. PMID: 42290558
4. Li X, Zhu P, Hu S (2026) The anti-leukemic effects of vitamin K4 by modulating the JAK/STAT signaling pathway. Cancer cell international. PMID: 42216158
5. Lukic D, Guzzi PH, Giorgi FM (2026) Integrated Evolutionary and Multi-Omic Analysis of STAT Family Activation Across Solid Tumors. Genes. PMID: 42195004
6. Kantakamalakul W, Jaroenpool J, Pattanapanyasat K (2003) A novel enhanced green fluorescent protein (EGFP)-K562 flow cytometric method for measuring natural killer (NK) cell cytotoxic activity. Journal of immunological methods. PMID: 12505723
7. Lim YJ, Marr B, Ghaziasgar S (2026) Development of Genetically Modified ARH-77 Feeder Cells for Efficient Expansion of Natural Killer Cells with Potent Anti-Tumor Activity. Cancers. PMID: 42279415
8. Badami C, Islamagic E, Blomén L (2026) BAP1 loss impairs IFN-γ signaling and enhances NK cell-mediated cytotoxicity in myeloid leukemia. Cancer immunology, immunotherapy : CII. PMID: 42295372
9. Cazote ADS, Mascarenhas GD, Perazzo H (2026) Functional Profile of γδ T Cells in Severe and Moderate COVID-19: A Brazilian Cross-Sectional Study. Cells. PMID: 42274612
10. Egorova AV, Lobova AM, Egorov DM (2026) Synthesis of Novel Acetylene-Containing Phosphonates, Their Antiviral Activity, and Their Cytotoxicity to Different Cancer Cell Lines. Molecules (Basel, Switzerland). PMID: 42280164
11. Jia L, Ding LF, Li JY (2026) Cassane-Type Diterpenoids From the Seeds of Caesalpinia pulcherrima and Their Cytotoxic Activities. Chemistry & biodiversity. PMID: 42246384
12. Nazemosadat-Arsanjani Z, Poustforoosh A, Pirhadi S (2026) Diterpenoid compounds isolated from Salvia majdae (Rech.f. & Wendelbo) Sytsma show antiproliferative and apoptosis inducing capacity against cancer cells. Natural product research. PMID: 42269004
13. Zhao QY, Yin SH, Sai L (2026) Eudesmane-type sesquiterpenoids with cytotoxic and anti-inflammatory activities from the fruits of Magnolia grandiflora. Fitoterapia. PMID: 42203113
14. Tiuleanu P, Ivanov IV, Andreeva IP (2026) Indole-2-carboxylic Acid Hydrazones and Hydroxamic Acid Derivatives: Synthesis and Evaluation of Biological Properties. Medicinal chemistry (Shariqah (United Arab Emirates)). PMID: 42300321
15. Lachinani L, Iranpour R, Forouzanfar M (2026) Tumor suppressor effects of miR-143 and miR-199 on the K562 myelogenous leukemia cell line by targeting the RNA-binding protein Musashi2. Scientific reports. PMID: 42230676
16. Xu C, Cui H, Fang Q (2026) Steamed Panax notoginseng saponins ameliorate cyclophosphamide-induced anemia by promoting erythroid progenitor proliferation via the cAMP/PI3K/AKT/cGMP pathway. Journal of ethnopharmacology. PMID: 42250832
17. Hu Y, Liu X, Wang H (2026) Efficiently electron beam radiation-induced degradation and extraction of Angelica sinensis polysaccharides and its excellent biofunctional properties. Food chemistry. PMID: 42235228